Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Billionaire Izzy Englander Doubling Down On This Medical Device Maker

Page 1 of 2

Israel Englander of Millennium Management has increased his stake in NuVasive, Inc. (NASDAQ:NUVA) according to a recent 13G form filed with the SEC. The billionaire investor has added to his holding in the $2.33 billion medical device company, now owning 2.55 million shares, up from 1.45 million shares held on March 31. The stake now amasses 5.3% of NuVasive, Inc’s outstanding shares.

Millennium Management, Catapult Capital Management

Let’s first take a step back and analyze how tracking hedge funds can help an everyday investor. Through our research we discovered that a portfolio of the 15 most popular small-cap picks of hedge funds beat the S&P 500 Total Return Index by nearly a percentage point per month on average between 1999 and 2012. On the other hand the most popular large-cap picks of hedge funds underperformed the same index by seven basis points per month during the same period. This is likely a surprise to many investors, who think of small-caps as risky, unpredictable stocks and put more faith in large-cap stocks. In forward tests since August 2012 these top small-cap stocks beat the market by an impressive 84 percentage points, returning over 142% (read the details here). Hence a retail investor needs to isolate himself from the herd, avoid excessive fees, and take advantage of the best growth opportunities in the market by concentrating on small-cap stocks, the best ideas of the best fund managers in the world.

In a recent meeting with Piper Jaffray’s Matt O’Brien, NuVasive, Inc. CFO Quentin Blackford said there was limited impact on the business due to the departures of COO Keith Valentine and CEO Alex Lukianov. He maintained that the revenue drivers are in place and the company expects to achieve or beat its sales target of $810M. Piper Jaffray is Overweight on the stock with a price target of $56, and O’Brien also believes the company or meet or beat its sales target.

Out of 700+ active hedge funds that are tracked by Insider Monkey, the interest in NuVasive, Inc. (NASDAQ:NUVA) was increased slightly during the first quarter, with 29 funds having invested $403.17 million in the company at the end of March compared to 26 funds with $332.30 million invested at the end of 2014. Ken Fisher’s Fisher Asset Management and Samuel Isaly’s Orbimed Advisors are two of the biggest stockholders of NuVasive in our database, with holdings of 1.55 million and 1.07 million shares respectively.

Let’s take a quick look at the top picks of Englander now, who was most bullish on the finance, healthcare, and energy sectors heading into the second quarter. The top three positions of the fund as of the end of the first quarter were Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), NextEra Energy, Inc. (NYSE:NEE), and American Electric Power Company, Inc. (NYSE:AEP).

A judge in Pennsylvania asked Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) to drop law firm Kirkland & Ellis LLP as its legal adviser concerning the ongoing Mylan Inc. (NASDAQ:MYL) acquisition talks. According to the judge, the law firm’s loyalty could be biased, having represented Mylan on previous drug approvals. Teva Pharmaceutical Industries Ltd’s $40 billion offer was rejected outright by Mylan NV paving the way for a three-way takeover battle between the two firms as well as Perrigo Company PLC Ordinary Shares (NYSE:PRGO), whom Mylan is attempting to acquire. Teva Pharmaceutical Industries Ltd has hired Sullivan & Cromwell LLP to advise it on how to proceed with the matter.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!